Gene · 84617
TUBB6: tubulin beta 6 class V
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. TUBB6: tubulin beta 6 class V. Genes, record 84617. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/84617
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q9BUF5 | Tubulin beta-6 chain | 446 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 5209 | Q9BUF5 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 4791 | Q9BUF5 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 4791 | Q9BUF5 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5209 | Q9BUF5 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5394 | Q9BUF5 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 93607 | Q9BUF5 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 196578 | Q9BUF5 | Espacenet |
| US 10463751 B2 | 2019-11-05 | 5394 | Q9BUF5 | Espacenet |
| JP 2018023373 A | 2018-02-15 | 28121 | Q9BUF5 | Espacenet |
| JP 2017148049 A | 2017-08-31 | 77 | Q9BUF5 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs91
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ABT-751 | CHEMBL20684 | Tubulin beta inhibitor | INHIBITOR | ChEMBL |
| AGS-16C3F | CHEMBL4594455 | Tubulin disrupting agent | DISRUPTING AGENT | ChEMBL |
| ANETUMAB RAVTANSINE | CHEMBL2109629 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANG1005 | CHEMBL1089636 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ANVATABART OPADOTIN | CHEMBL4297892 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| APRUTUMAB IXADOTIN | CHEMBL4650293 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| ASG-5ME | CHEMBL2109574 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AVE-9633 | CHEMBL2109266 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| AZINTUXIZUMAB VEDOTIN | CHEMBL4297859 | Tubulin inhibitor | INHIBITOR | ChEMBL |
| BELANTAMAB MAFODOTIN | CHEMBL4298209 | Tubulin inhibitor | INHIBITOR | ChEMBL |
1 to 10 of 91
See all 91 drugsTrials8,740
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604766 | PACLITAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07602907 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601737 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07601178 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07599163 | PACLITAXEL | ClinicalTrials.gov | ||
| NCT07595770 | PACLITAXEL | PHASE2 | ClinicalTrials.gov | |
| NCT07594548 | PACLITAXEL | PHASE1 | ClinicalTrials.gov | |
| NCT07591467 | DOCETAXEL | PHASE3 | ClinicalTrials.gov | |
| NCT07589972 | VINORELBINE | ClinicalTrials.gov | ||
| NCT07588698 | VINCRISTINE SULFATE | PHASE2 | ClinicalTrials.gov |
1 to 10 of 8,740
See all 8,740 trialsNIH grants599
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | TUBB6 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R01GM094231 | COMPUTATIONAL TOOLS FOR MASS SPECTROMETRY-BASED INTERACTOME DATA | 3 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 2 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 2 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 2 | 2025 |
| P50HD105351 | Boston Children's Hospital/HMS Intellectual and Developmental Disabilities Research Center | 2 | 2025 |
| R01GM141109 | Mechanoregulation of Ciliary Motility | 2 | 2025 |
| R01MH115957 | Scalable tool and comprehensive maps to interpret structural variation across the neuropsychiatric spectrum | 2 | 2025 |
| R01NS058721 | ACC: Callosal Agenesis as a Window into Common Neurodevelopmental Disorders | 2 | 2025 |
1 to 10 of 599Source NIH's project files
See all 599 nih grantsPapers729
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development and validation of cell-free RNA-based predictive models for preeclampsia using placental single-cell transcriptomic data. | J Reprod Immunol | 2026 | 42623724 | PubTator, text mining | PubMed |
| MIS12 Is Required for Kinetochore-Microtubule Attachment in Oocyte Meiosis. | Adv Sci (Weinh) | 2026 | 42338338 | PubTator, text mining | PubMed |
| Investigating the Function of C‑Terminal Tails of Human Tubulin Isotypes in the Motility Regulation of Cytoplasmic Dynein. | ACS Omega | 2026 | 42179625 | PubTator, text mining | PubMed |
| Overexpression of the erythropoietin receptor is associated with upregulation of tubulin beta 6 and paclitaxel resistance in ovarian adenocarcinoma cells. | Acta Chim Slov | 2026 | 41918423 | PubTator, text mining | PubMed |
| Genome-wide DNA methylation profiles and ribosomal DNA copy number at birth. | Epigenetics | 2026 | 41774615 | PubTator, text mining | PubMed |
| Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods. | Diseases | 2026 | 41745104 | PubTator, text mining | PubMed |
| Single-cell analysis reveals the cellular and transcriptional heterogeneity of the normal pediatric thyroid. | Front Endocrinol (Lausanne) | 2026 | 41727685 | PubTator, text mining | PubMed |
| DRP1 depletion protects NK cells from hypoxia-induced dysfunction. | Redox Rep | 2026 | 41706678 | PubTator, text mining | PubMed |
| Expanding genetic and clinical spectra of β-tubulinopathies: A Korean study. | J Hum Genet | 2026 | 41152456 | PubTator, text mining | PubMed |
| Lactate metabolism orchestrates immune dysregulation in renal cancer: A multi-omics and causal inference study. | Sci Prog | 2025 | 41406083 | PubTator, text mining | PubMed |
1 to 10 of 729
See all 729 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/84617
GET https://conductscience.org/api/genes/v1/84617/patents?page=2